Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

OBJECTIVE: This study aimed to assess the efficacy and safety of 2 Janus kinase (JAK) inhibitors (jakinibs) tofacitinib and ruxolitinib in the treatment of type I interferonopathies patients including STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutières syndrome (AGS), and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wendao, Wang, Wei, Zhong, Linqing, Gou, Lijuan, Wang, Changyan, Ma, Jingran, Quan, Meiying, Jian, Shan, Tang, Xiaoyan, Zhang, Yu, Wang, Lin, Ma, Mingsheng, Song, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995420/
https://www.ncbi.nlm.nih.gov/pubmed/35418997
http://dx.doi.org/10.3389/fimmu.2022.825367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995420/
https://www.ncbi.nlm.nih.gov/pubmed/35418997
http://dx.doi.org/10.3389/fimmu.2022.825367

Ejemplares similares